Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | FFAR4 | Q5NUL3 | 13/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 5/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7399173 | 0.89 | CYP1A2 (0.41) | CYP1A2HTTFOLH1FFAR4FFAR1 | |
| SCHEMBL29852059 | 0.87 | CYP1A2 (0.40) | CYP1A2HTTFOLH1FFAR4FFAR1 | |
| SCHEMBL9857060 | 0.86 | CYP1A2 (0.63) | CYP1A2 | |
| SCHEMBL29851943 | 0.86 | CYP1A2 (0.39) | CYP1A2HTTFOLH1FFAR4FFAR1 | |
| SCHEMBL3278372 | 0.85 | CYP1A2 (0.51) | CYP1A2CA1CA9 | |
| SCHEMBL10686823 | 0.83 | CYP1A2 (0.50) | CYP1A2CA1CA9 | |
| SCHEMBL3621337 | 0.83 | CYP1A2 (0.54) | CYP1A2CA1CA9 | |
| SCHEMBL2406971 | 0.82 | CYP1A2 (0.46) | CYP1A2CA1CA9 | |
| Methoxymethane SCHEMBL29851917 | 0.82 | CYP1A2 (0.40) | CYP1A2HTTFOLH1FFAR4FFAR1 | |
| SCHEMBL3280318 | 0.81 | CYP1A2 (0.53) | CYP1A2CA1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115461055-A | Prodrugs of neuroactive steroids | 腾盛博药生物科技有限公司 | 2022-12-09 | — | — | CN | claimed |
| EP-2278975-B1 | NOVEL NITROSO COMPOUNDS AS NITROXYL DONORS AND METHODS OF USE THEREOF | CARDIOXYL PHARMACEUTICALS INC (US) | 2016-09-07 | — | — | EP | claimed |
| US-20250326731-A1 | CATALYST-CONTROLLED SITE-SELECTIVE METHYLENE C-H LACTONIZATION OF DICARBOXYLIC ACIDS | SCRIPPS RESEARCH INST (US) | 2025-10-23 | — | — | US | disclosed |
| EP-4522595-A2 | CATALYST-CONTROLLED SITE-SELECTIVE METHYLENE C-H LACTONIZATION OF DICARBOXYLIC ACIDS | The Scripps Research Institute (US) | 2025-03-19 | — | — | EP | disclosed |
| CN-115461055-B | Prodrugs of neuroactive steroids | 腾盛博药生物科技有限公司 | 2025-01-28 | — | — | CN | disclosed |
| US-20230416298-A1 | PRODRUGS OF NEUROACTIVE STEROIDS | BRII BIOSCIENCES, INC. | 2023-12-28 | — | — | US | disclosed |
| WO-2023220559-A2 | CATALYST-CONTROLLED SITE-SELECTIVE METHYLENE C-H LACTONIZATION OF DICARBOXYLIC ACIDS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023220559-A2 | CATALYST-CONTROLLED SITE-SELECTIVE METHYLENE C-H LACTONIZATION OF DICARBOXYLIC ACIDS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2023-11-16 | — | — | WO | disclosed |
| EP-4110345-A1 | PRODRUGS OF NEUROACTIVE STEROIDS | Brii Biosciences, Inc. (US) | 2023-01-04 | — | — | EP | disclosed |
| CN-115461055-A | Prodrugs of neuroactive steroids | 腾盛博药生物科技有限公司 | 2022-12-09 | — | — | CN | disclosed |
| US-9732029-B2 | Nitroso compounds as nitroxyl donors and methods of use thereof | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2017-08-15 | — | — | US | disclosed |
| US-8318705-B2 | Nitroso compounds as nitroxyl donors and methods of use thereof | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2012-11-27 | — | — | US | disclosed |
| EP-2278975-A1 | NOVEL NITROSO COMPOUNDS AS NITROXYL DONORS AND METHODS OF USE THEREOF | Cardioxyl Pharmaceuticals Inc. (US) | 2011-02-02 | — | — | EP | disclosed |
| WO-2009137717-A1 | NOVEL NITROSO COMPOUNDS AS NITROXYL DONORS AND METHODS OF USE THEREOF | CARDIOXYL PHARMACEUTICALS INC. (US) | 2009-11-12 | — | — | WO | disclosed |
| US-20090281062-A1 | NOVEL NITROSO COMPOUNDS AS NITROXYL DONORS AND METHODS OF USE THEREOF | EVOTEC LTD. (GB) | 2009-11-12 | — | — | US | disclosed |
| US-4939147-A | Substituted 3,4-dihydroxy phenylethylamino compounds | FISONS PLC. (GB) | 1990-07-03 | — | — | US | disclosed |
| US-4922022-A | Substituted 3,4-dihydroxy phenylethylamino compounds | FISONS PLC (GB) | 1990-05-01 | — | — | US | disclosed |
| EP-0314725-A1 | 2-(3,4-DIHYDROXYPHENYL)ETHYLAMINES, THEIR PREPARATION AND USE AS PHARMACEUTICAL | FISONS plc (GB) | 1989-05-10 | — | — | EP | disclosed |
| WO-1988009326-A1 | 2-(3,4-DIHYDROXYPHENYL)ETHYLAMINES, THEIR PREPARATION AND USE AS PHARMACEUTICAL | FISONS PLC (GB) | 1988-12-01 | — | — | WO | disclosed |
| EP-0292202-A1 | 2-(3,4-Dihydroxyphenyl ethyl amines, their preparation and use as pharmaceutical compounds | FISONS plc (GB) | 1988-11-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250326731-A1 | CATALYST-CONTROLLED SITE-SELECTIVE METHYLENE C-H LACTONIZATION OF DICARBOXYLIC ACIDS | DNPH1, NISCH, PTMA | CYP1A2 3500/4885HTT 3294/4885FOLH1 150/4885 |
| US-20230416298-A1 | PRODRUGS OF NEUROACTIVE STEROIDS | NR3C1, PGR, GABRD | CYP1A2 225/4885HTT 3995/4885FOLH1 3951/4885 |
| US-20090281062-A1 | NOVEL NITROSO COMPOUNDS AS NITROXYL DONORS AND METHODS OF USE THEREOF | NOXO1, TNNI3, HAO2 | CYP1A2 2023/4885HTT 2710/4885FOLH1 3697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.